Conditions: Pancreatic Cancer
Keywords: Pancreas
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 2
Healthy volunteers: no

Brief summary:
To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.

Detailed description:
To determine the response rate by RECIST criteria.

To determine the progression free survival.

To determine the median survival and overall survival at one year.

Arms:
arm 1: Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle.

Pazopanib 800 mg PO daily of each 28 day cycle.

Interventions: intervention 1: Gemcitabine intervention 2: Pazopanib
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: